• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
CardioCell

CardioCell

Breakthrough Cardiovascular Technology

  • About Us
    • Overview
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Our Stem Cells
    • Manufacturing
    • Quality Control
    • Exclusive License
  • Clinical Trials
    • Overview
    • Chronic Heart Failure
    • Heart Failure in Patients With Left Ventricular Assist Devices
    • Acute Myocardial Infarction
  • News
    • Press Releases
    • Media Coverage
    • Publications
  • Events
  • LinkedIn

News

April 3, 2014

CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure

News Apr 3, 2014 CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure CardioCell LLC has just received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell

Read More

Media Coverage

April 2, 2014

FDA grants IND approval for CardioCell’s phase IIa itMSC Therapy trial

News Apr 2, 2014 FDA grants IND approval for CardioCell’s phase IIa itMSC Therapy trial CardioCell, a global biotechnology company, has just received the FDA’s Investigational New Drug (IND) approval for a U.S.-based, phase IIa clinical study using its allogeneic stem-cell therapy to

Read More

Media Coverage

April 2, 2014

FDA Gives Go-Ahead for Phase 2a Trial of CardioCell CHF Stem Cell Therapy

News Apr 2, 2014 FFDA Gives Go-Ahead for Phase 2a Trial of CardioCell CHF Stem Cell Therapy CardioCell LLC has just received the FDA’s investigational new drug (IND) approval for a United States-based, Phase 2a clinical study using its allogeneic stem-cell therapy to treat subjects

Read More

Media Coverage

April 2, 2014

CardioCell gets IND approval from FDA

News Apr 2, 2014 CardioCell gets IND approval from FDA San Diego-based CardioCell LLC on Wednesday received the Food and Drug Administration’s investigational new drug (IND) approval for a phase 2a clinical study using its allogeneic stem-cell therapy to treat subjects with chronic

Read More

Media Coverage

April 2, 2014

FDA Grants IND Approval For Phase 2a Clinical Trial Using CardioCell’s Itmsc Therapy To Treat Dilated Chronic Heart Failure

News Apr 2, 2014 FDA Grants IND Approval For Phase 2a Clinical Trial Using CardioCell’s Itmsc Therapy To Treat Dilated Chronic Heart Failure CardioCell LLC has just received the FDA’s investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using

Read More

Media Coverage

April 2, 2014

FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell’s itMSC Therapy to Treat Dilated Chronic Heart Failure

News Apr 2, 2014 FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell’s itMSC Therapy to Treat Dilated Chronic Heart Failure SAN DIEGO — April 2, 2014 — CardioCell LLC has just received the FDA’s investigational new drug (IND) approval for a United States-based,

Read More

Press Releases

  • « Previous Page
  • Page 1
  • …
  • Page 10
  • Page 11
  • Page 12

Primary Sidebar

Categories

  • Events
  • Media Coverage
  • News
  • Press Releases
  • Publications

Footer

About Us

  • Overview
  • Board of Directors
  • Scientific Advisory Board

Technology

  • Our Stem Cells
  • Manufacturing
  • Quality Control
  • Exclusive License

Clinical Trials

  • Overview
  • Chronic Heart Failure
  • Heart Failure in Patients With Left Ventricular Assist Devices
  • Acute Myocardial Infarction
<section id="bpfwp_contact_card_widget-1" class="widget widget_bpfwp_contact_card_widget"><div class="widget-wrap"><h3 class="widgettitle widget-title">Contact</h3>
info@stemcardiocell.com
</div></section>

Copyright © 2023 · Business Pro Theme on Genesis Framework · WordPress · Log in